American Well Corp (AMWL) Q3 2026 Earnings Call Highlights: Revenue Beat, Raised Guidance

American Well Corp (AMWL) reported Q3 2026 revenue of $49M, down 12.9% YoY. Subscription revenue fell 22.5% due to churn. Platform visits dropped 30.5% YoY. The VA letter of intent is non-binding, and the DHA contract conversion is pending. CEO Dr. Ido Schoenberg expressed optimism about negotiations and potential growth opportunities. The company expects Q4 adjusted EBITDA breakeven and raised guidance.

Original reporting
Published Nov 4, 2026, 5:10 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 4, 2026, 5:30 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
American Well Corp (AMWL) Q3 2026 Earnings Call Highlights: Revenue Beat, Raised Guidance — source image
Decision brief

The 30-second read

$AMWLNeutralMed
01

Why it matters

Near-term revenue visibility is constrained by non-binding LOI status and unknown VA start date, while longer-term upside depends on converting agreements and scaling outcomes-based clinical services.

02

Market read

Traders can reassess the balance between raised guidance and the timing risk of VA definitive contracting, which the company says could affect revenue recognition into 2027.

03

What to watch

Investors may underweight the operational momentum signals (3x engagement, 4.9/5 member ratings, virtual primary care visits up 40% YoY) that could improve utilization-driven revenue mix even if subscription growth remains choppy.

Relevance 7/10Novelty 6/10Timing: ahead of the next earnings call where full-year 2027 guidance will be provided

Background

The call centers on Amwell’s government payer contracting path (VA letter of intent to definitive contract, DHA conversion to longer-term direct agreement) and its subscription churn dynamics.

Company-level read

Ticker impact

$AMWLNeutralHigh confidence
Context

Amwell reported Q3 2026 call highlights including revenue decline, churn details, and guidance raised, with VA LOI and DHA conversion timing uncertainty.

Expected impact

Likely mixed reaction, with upside from raised guidance tempered by uncertainty around VA definitive contract timing and ongoing churn.

Evidence & confidence

The article provides both positive (raised guidance, engagement/outcomes metrics) and negative (12.9% revenue decline, subscription revenue down 22.5%, platform visits down 30.5%, VA LOI non-binding, start date unknown) items, making direction dependent on how investors weigh guidance versus timing risk.

Market effects

Reinforces that virtual care and payer-facing SaaS models are being judged on outcomes-based monetization and churn control, not just top-line growth.

No clear regional spillover beyond US healthcare IT and virtual care investor sentiment.

Limited, as the catalysts described are US government payer contracting and company-specific guidance.

Counterpoint

The raised guidance may be less durable if VA revenue is delayed into 2027 and subscription churn from de-emphasized businesses persists.

Key entities

  • American Well Corp

    Subject of the earnings call highlights, including revenue/churn performance and guidance raised amid VA and DHA contracting uncertainty.

  • Dr. Ido Schoenberg

    CEO quoted on contract negotiations, engagement/outcomes metrics, and expectations for breakeven and growth drivers.

  • Mark Hirschhorn

    CFO/COO quoted on Q4 EBITDA breakeven expectations and churn/guidance framing.

Related articles

$AMWLMedAI 8/10

What American Well (AMWL) Said on Its Q3 Earnings Call

Amwell (AMWL) reported Q3 earnings with virtual primary care visits up 41% YoY, but total platform visits down 30.5%. Gross profit was $26M with a 53% margin. Q4 revenue is forecasted at $48M-$50M, with adjusted EBITDA expected to break even or turn positive. The company raised its full-year 2026 outlook, now expecting revenue of $204M-$206M and a reduced adjusted EBITDA loss. Amwell also discussed potential government contracts, including a nonbinding letter of intent from the VA.

$AMWLHigh

American Well Corp (AMWL): AMWELL® ANNOUNCES RESULTS FOR THE third QUARTER 2026

American Well Corp (AMWL) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 AMWELL® ANNOUNCES RESULTS FOR THE third QUARTER 2026 BOSTON, November 3 , 2026 –Amwell ® (NYSE: AMWL), a leading provider of a comprehensive SaaS-based technology-enabled healthcare platform, today announced financial results for the third quarter ended September 30,

$AMWLMedAI 8/10

American Well (AMWL) Q2 2026 Earnings Call Transcript

American Well (AMWL) reported Q2 2026 revenue of $52 million, down 26.6% year over year, with subscription revenue of $25.7 million and AMG revenue of $24.4 million. Adjusted EBITDA loss was $1.15 million and net loss was $9.6 million. Full-year guidance was narrowed to $200-$205 million revenue and improved adjusted EBITDA loss to $9-$7 million. The Defense Health Agency issued an intent to award a sole-source contract.

$AMWLMed

American Well Corp (AMWL): AMWELL® ANNOUNCES RESULTS FOR THE Second QUARTER 2026

American Well Corp (AMWL) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 AMWELL® ANNOUNCES RESULTS FOR THE Second QUARTER 2026 BOSTON, August 4 , 2026 –Amwell ® (NYSE: AMWL), a leading provider of a comprehensive SaaS-based technology-enabled healthcare platform, today announced financial results for the second quarter ended June 30, 2026